ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Ceralasertib is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 3:40 AM UTC“With trastuzumab deruxtecan in HER2-expressing tumours”
  • The role rule says the same.
  • So Ceralasertib's page lists this study under “Testing it”.
11 links0 made here, not in the record5 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04704661Testing the Combination ofTwo Anti-cancer Drugs,DS-8201a and AZD6738, forThe Treatment of AdvancedSolid Tumors Expressing theHER2 Protein or Gene, TheDASH TrialNational Cancer Institute (NCIPhase 1 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSBreast NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Colonic NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Colorectal NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Endometrial NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Stomach NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Neoplasm MetastasisThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Salivary Gland NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.CarcinosarcomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSCeralasertibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumab deruxtecanIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
2 versions of the record seen on ClinicalTrials.gov, Nov 12–Nov 18 · changes seen, not judgments
Nov 2CeralasertibClaude Opus 5.5TestedCurrent
Nov 2Trastuzumab deruxtecanClaude Opus 5.5Background · partnerCurrent
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
Nov 18CeralasertibRule based · role ruleTestedAgrees
Nov 18Trastuzumab deruxtecanRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.